Erin Rasch, Vice President of Sales and Business Development for Be The Match BioTherapies

Maintaining business continuity during COVID-19

Just like for all businesses, March 2020 began what would become months of uncharted territory for our Be The Match BioTherapies® team. Overnight, travel to visit with cell therapy partners and potential clients was grounded. Conferences where connections are made…canceled. Even team meetings that were once in person moved online. But through these challenges, resiliency…

Scaling cell therapy supply chains during a pandemic

Travel disruptions caused by COVID-19 have meant little more than delayed holidays or missed work meetings for most of us. They’re inconveniences, but hardly life-threatening challenges. But for patients who depend on cell therapies to provide potentially curative treatments, the pandemic’s canceled flights and closed borders have posed a real threat to their wellbeing. In…

5 qualities to seek in your cell therapy supply chain vendor

As your cell or gene therapy operations scale from early-phase clinical trials to larger populations in late-stage trials and commercialization, your supply chain complexity — and risk — increases. Anticipating common setbacks and actively planning for their solution requires a specialized and collaborative approach with your supply chain partner. Keep these key considerations top of…

Depiction of international autologous cell therapy logistics.

Overcoming autologous cell therapy logistics challenges in the age of COVID-19

There is no question the COVID-19 pandemic has disrupted cell therapy logistics like never before. Supply chain challenges are no longer the exception, but the norm. So how can companies overcome autologous cell therapy logistics challenges to deliver time-sensitive source material and manufactured therapies on time? It’s not easy in our current environment, but it…

Representation of NMDP/Be The Match donor collection network

Managing donor collections during the COVID-19 pandemic

Even before COVID-19 reached pandemic levels, teams at the National Marrow Donor Program® (NMDP)/Be The Match® had their eye on an important part of the cell therapy supply chain—donor collections. Collections from allogeneic donors are critical to getting time-sensitive life-saving cell therapies to patients around the world. But donors often must fly to the apheresis…

COVID-19

Navigating a time-sensitive cell therapy supply chain during the coronavirus outbreak (Updated)

Updated March 27, 2020 (original story follows) Editor’s note: It’s been just over one month since we first shared how established relationships have helped our organization navigate the impacts of the coronavirus on the cell therapy supply chain. Since then, much has changed. Just a few days after we posted the story, reports from Italy…

How to overcome 3 common cell therapy supply chain disruptions

One patient, one product. The successful on-time delivery of cell and gene therapies isn’t just good business—it’s a matter of survival for patients. When there’s no room for mistakes, an advanced approach is needed to overcome supply chain disruptions that create barriers to successful on-time delivery. Severe weather, customs complexities and flight delays are three…